MedPacto, Inc.
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 2013-06-19
- Employees
- 63
- Market Cap
- -
- Website
- http://www.medpacto.com
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06219733
- Locations
- π°π·
Yeonsei University Severance Hospital, Seoul, Korea, Republic of
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05588648
- Locations
- πΊπΈ
UH Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States
π°π·National Cancer Center, Gyeonggi-do, Korea, Republic of
π°π·Korea Institute of Radiological & Medical Sciences, Seoul, Korea, Republic of
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04515979
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
- Conditions
- Urothelial Carcinoma RecurrentAdvanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04064190
- Locations
- πΊπΈ
University of California San Francisco, San Francisco, California, United States
πΊπΈRoswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03732274
- Locations
- π°π·
Yeonsei University Hospital, Seoul, Korea, Republic of
π°π·ChungBuk national university hospital, Chungju, Korea, Republic of
π°π·National Cancer Center, Goyang-si, Korea, Republic of
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
- Conditions
- Metastatic Colorectal CancerGastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03724851
- Locations
- π°π·
Yeonsei University Hospital, Seoul, Korea, Republic of
π°π·National Cancer Center, Goyang, Korea, Republic of
π°π·Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03704675
- Locations
- π°π·
Inje University Busan Paik Hospital, Busan, Korea, Republic of
TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT03698825
- Locations
- π°π·
Hallym University Medical Center, Anyang-si, Korea, Republic of
π°π·Shinchon Severance, Seoul, Korea, Republic of
π°π·Gangnam Severance, Seoul, Korea, Republic of
Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03074006
- Locations
- πΊπΈ
Site 01, Bronx, New York, United States
πΊπΈSite 02, Baltimore, Maryland, United States
πΊπΈSite 03, Tampa, Florida, United States
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02160106